Final appraisal document: Erenumab for preventing migraine

In DRAFT guidance, NICE recommends erenumab for preventing migraine in adults, only if: they have 4 or more migraine days a month; at least 3 preventive drug treatments have failed; the 140 mg dose of erenumab is used and it is provided according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence